| scholarly article | Q13442814 |
| P2093 | author name string | Kenneth E Sherman | |
| Maria D Hernandez | |||
| P2860 | cites work | Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review | Q27489337 |
| The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 | Q33726091 | ||
| Hepatitis C infection in HIV-1 natural viral suppressors. | Q33952520 | ||
| Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: Implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis | Q34049020 | ||
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study | Q34269641 | ||
| HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies | Q34561257 | ||
| HIV infection increases HCV-induced hepatocyte apoptosis | Q34699457 | ||
| Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus | Q35018396 | ||
| Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells | Q35077992 | ||
| The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985 | Q35362239 | ||
| CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis | Q35847699 | ||
| Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis | Q36218336 | ||
| Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination | Q37128257 | ||
| Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis | Q37265953 | ||
| Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 | ||
| Hepatitis C virus infection sensitizes human hepatocytes to TRAIL-induced apoptosis in a caspase 9-dependent manner | Q39938266 | ||
| Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy | Q42979572 | ||
| HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection | Q42986755 | ||
| Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression | Q42986831 | ||
| Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. | Q42997118 | ||
| Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy | Q42998831 | ||
| Immunological status does not influence hepatitis c virus or liver fibrosis in HIV-hepatitis C virus-coinfected patients | Q43000875 | ||
| The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients | Q43034421 | ||
| The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. | Q43035585 | ||
| Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group | Q43036483 | ||
| HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension | Q44561456 | ||
| Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy | Q45424761 | ||
| Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study | Q45506960 | ||
| Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study | Q45739390 | ||
| Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. | Q45765994 | ||
| Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. | Q46719182 | ||
| Hepatitis C Virus Infection in HIV-infected Patients | Q74519531 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 478-482 | |
| P577 | publication date | 2011-11-01 | |
| P1433 | published in | Current Opinion in HIV and AIDS | Q15724409 |
| P1476 | title | HIV/hepatitis C coinfection natural history and disease progression | |
| P478 | volume | 6 |
| Q37149637 | 14-3-3s are potential biomarkers for HIV-related neurodegeneration |
| Q38936312 | Aging of the Liver: What This Means for Patients with HIV. |
| Q36336081 | Alterations of the NK cell pool in HIV/HCV co-infection |
| Q41662784 | Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana. |
| Q92200850 | Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection |
| Q35860136 | Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? |
| Q36840571 | Association of hepatitis C with markers of hemostasis in HIV-infected and uninfected women in the women's interagency HIV study (WIHS). |
| Q35795095 | CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba |
| Q34702334 | Care at the Crossroads: Navigating the HIV, HCV, and Substance Abuse Syndemic |
| Q37730962 | Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study |
| Q26781789 | Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C |
| Q39497261 | Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010. |
| Q36533831 | Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life |
| Q33597796 | Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of China |
| Q40846320 | Discordant response of CD4(+) T cells to antiretroviral therapy in HIV-infected patients coinfected with hepatitis C virus is accompanied by increased liver damage. |
| Q40109601 | Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy |
| Q45255359 | Editorial: direct-acting anti-virals - not the be-all and end-all in HIV/HCV co-infection |
| Q40621844 | Effect of Hepatitis C Virus Coinfection on the Content of CD4(+) and CD8(+) T Cell Subpopulations in HIV-Infected Patients Receiving Antiretroviral Therapy |
| Q40328514 | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study |
| Q58603882 | Era of direct acting anti-viral agents for the treatment of hepatitis C |
| Q61444344 | Fibrogenic Gene Expression in Hepatic Stellate Cells Induced by HCV and HIV Replication in a Three Cell Co-Culture Model System |
| Q36316589 | HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells |
| Q37098372 | HCV treatment in children and young adults with HIV/HCV co-infection in Europe |
| Q27004165 | HIV infection, aging, and immune function: implications for cancer risk and prevention |
| Q41760166 | Hepatic compartmentalization of exhausted and regulatory cells in HIV/HCV-coinfected patients |
| Q35095416 | Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia |
| Q28084654 | Hepatitis C |
| Q38391718 | Hepatitis C and HIV Coinfection for Social Workers in Public Health, Medical and Substance Use Treatment Settings |
| Q38249236 | Hepatitis C virus genotype 3: a genotype that is not 'easy-to-treat'. |
| Q40082158 | High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic |
| Q26991958 | Immuno-pathomechanism of liver fibrosis: targeting chemokine CCL2-mediated HIV:HCV nexus |
| Q40457693 | Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes. |
| Q58704386 | Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients |
| Q30364549 | Infection of female primary lower genital tract epithelial cells after natural pseudotyping of HIV-1: possible implications for sexual transmission of HIV-1. |
| Q42680423 | Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders |
| Q91726433 | Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir |
| Q35191924 | Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients. |
| Q45072392 | Mechanisms of liver disease in patients infected with HIV. |
| Q33907429 | Molecular mechanisms of liver fibrosis in HIV/HCV coinfection |
| Q26773264 | Natural killer cells in hepatitis C: Current progress |
| Q36344202 | Opportunities in proteomics to understand hepatitis C and HIV coinfection |
| Q92923431 | Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran |
| Q35105508 | Periportal CD4+ cell infiltration increases in HIV/hepatitis C virus-coinfected patients commencing ART, whereas CD8+ cells clear from the liver. |
| Q64232429 | Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria |
| Q28550423 | Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients |
| Q64101170 | Sero-prevalence of Hepatitis B and C viral co-infections among HIV-1 infected ART-naïve individuals in Kumasi, Ghana |
| Q51862034 | Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. |
| Q37111444 | Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients |
| Q36090286 | Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States |
| Q50056378 | Successful treatment of HIV-/HCV-coinfected patients in the era of direct acting antivirals: is advanced liver disease still a limiting factor? |
| Q38103293 | Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection |
| Q35742761 | The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action |
| Q40224914 | The changing epidemiology of HIV in the criminal justice system |
| Q41075768 | The dollars and sense of chronic hepatitis C infection management |
| Q28081282 | The potential impact of coinfection on antimicrobial chemotherapy and drug resistance |
| Q38793776 | Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature |
Search more.